Costly Information in Firm Transformation, Exit, or Persistent Failure
AbstractFirms invest differentially in the intellectual human capital required to recognize, evaluate, and utilize technological breakthroughs occurring outside the firm. Such differential investment has been crucial in explaining which incumbent pharmaceutical firms have successfully transformed their technological identities in response to the biotechnological revolution and which are threatened by persistent low performance. While all incumbent firms lagged the dedicated new biotechnology firms in adopting the new drug-discovery technology, firms with higher R&D expenditures before the biotech revolution were more likely to successfully adopt the new techniques and likely to do so earlier. Failure to adopt the new techniques was associated with lower performance compared to firms adopting more fully and faster.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by National Bureau of Economic Research, Inc in its series NBER Working Papers with number 5577.
Date of creation: Nov 1996
Date of revision:
Contact details of provider:
Postal: National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.
Web page: http://www.nber.org
More information through EDIRC
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Darby, Michael R, 1976.
"Rational Expectations under Conditions of Costly Information,"
Journal of Finance,
American Finance Association, vol. 31(3), pages 889-95, June.
- Michael R. Darby, 1974. "Rational Expectations Under Conditions of Costly Information," UCLA Economics Working Papers 045, UCLA Department of Economics.
- Lynne G. Zucker & Michael R. Darby, 1999. "Present at the Revolution: Transformation of Technical Identity for a Large Incumbent Pharmaceutical Firm After the Biotechnological Breakthrough," NBER Working Papers 5243, National Bureau of Economic Research, Inc.
- Zucker, Lynne G & Darby, Michael R & Brewer, Marilynn B, 1998. "Intellectual Human Capital and the Birth of U.S. Biotechnology Enterprises," American Economic Review, American Economic Association, vol. 88(1), pages 290-306, March.
- Lynne G. Zucker & Michael R. Darby & Marilynn B. Brewer & Yusheng Peng, 1995. "Collaboration Structure and Information Dilemmas in Biotechnology: Organizational Boundaries as Trust Production," NBER Working Papers 5199, National Bureau of Economic Research, Inc.
- Patricia M. Danzon & Allison Percy, 1999. "The Effects of Price Regulation on Productivity in Pharmaceuticals," NBER Chapters, in: International and Interarea Comparisons of Income, Output, and Prices, pages 371-418 National Bureau of Economic Research, Inc.
- Hanson, Gordon H, 1995. "Incomplete Contracts, Risk, and Ownership," International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, vol. 36(2), pages 341-63, May.
- Lynne G. Zucker & Michael R. Darby & Jeff Armstrong, 1999. "Intellectual Capital and the Firm: The Technology of Geographically Localized Knowledge Spillovers," NBER Working Papers 4946, National Bureau of Economic Research, Inc.
- Schivardi, Fabiano & Schneider, Martin, 2005.
"Strategic Experimentation and Disruptive Technological Change,"
CEPR Discussion Papers
4925, C.E.P.R. Discussion Papers.
- Fabiano Schivardi & Martin Schneider, 2008. "Strategic Experimentation and Disruptive Technological Change," Review of Economic Dynamics, Elsevier for the Society for Economic Dynamics, vol. 11(2), pages 386-412, April.
- Zucker, Lynne G. & Darby, Michael R., 1997. "Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm," Research Policy, Elsevier, vol. 26(4-5), pages 429-446, December.
- McMillan, G. Steven & Narin, Francis & Deeds, David L., 2000. "An analysis of the critical role of public science in innovation: the case of biotechnology," Research Policy, Elsevier, vol. 29(1), pages 1-8, January.
- Lynne G. Zucker & Michael R. Darby, 2007. "Star Scientists, Innovation and Regional and National Immigration," NBER Working Papers 13547, National Bureau of Economic Research, Inc.
- Lynne G. Zucker & Michael R. Darby & Yusheng Peng, 1998. "Fundamentals or Population Dynamics and the Geographic Distribution of U.S. Biotechnology Enterprises, 1976-1989," NBER Working Papers 6414, National Bureau of Economic Research, Inc.
- Peter Arbo & Heikki Eskelinen, 2003. "The Role of Small, Comprehensive Universities in Regional Economic Development: Experiences from Two Nordic cases," ERSA conference papers ersa03p530, European Regional Science Association.
- Davis, Lee, 1999. "R&D Investments, Information and Strategy," Working Papers 10-1999, Copenhagen Business School, Department of International Economics and Management.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ().
If references are entirely missing, you can add them using this form.